NCT07016633View on ClinicalTrials.gov

To Evaluate the Tolerability, Pharmacokinetics, and Pharmacodynamics of IMM-H014 in Patients With MASH

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

June 10, 2025

Primary Completion Date

June 1, 2027

Study Completion Date

December 1, 2027

Conditions
Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Interventions
DRUG

IMM-H014

Each group will consist of 10 participants who will be randomly assigned to receive IMM-H014 and placebo in a ratio of 4:1, once a day for a total of 12 weeks.

DRUG

Placebo

Each group will consist of 10 participants who will be randomly assigned to receive IMM-H014 and placebo in a ratio of 4:1, once a day for a total of 12 weeks.

Trial Locations (1)

Unknown

The first Bethune hospital of Jilin University, Changchun

All Listed Sponsors
lead

Changchun Intellicrown Pharmaceutical Co. LTD

INDUSTRY

NCT07016633 - To Evaluate the Tolerability, Pharmacokinetics, and Pharmacodynamics of IMM-H014 in Patients With MASH | Biotech Hunter | Biotech Hunter